Flowonix, a company out of Mt. Olive, New Jersey, and Cerebral Therapeutics of Aurora, Colorado, have announced that the Prometra II infusion device they jointly developed has been installed in the first patients in a clinical trial. The trial at the St. Vincent’s Hospital in Melbourne, Australia involves patients with medically refractory epilepsy receiving valproate (valproate sodium) delivered directly into their brains from the Prometra II.
In total, nine patients will be implanted with the device to evaluate whether this therapy reduces the frequency of seizures.
The pump has a battery lifetime of approximately 10 years, and it can be programmed externally by a physician. It can be refilled using a syringe, even hundreds of times thanks to a silicone barrier.
Product page: Prometra Programmable Pump…